InvestSMART

PainChek Ltd (ASX: PCK) - Announcements

Current share price for PCK : $0.093 0.001 (1.09%)+

ASX company news and announcements for PainChek Ltd (PCK) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PainChek Ltd (PCK) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PainChek Ltd (PCK), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PainChek Ltd (PCK)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$19 Lil Bianchi appointed Non-Executive Chair of PainChek 25 May 2026 8:50AM $0.140 $0.093 fallen by 33.57%
$19 Proposed issue of securities - PCK 22 May 2026 1:53PM $0.145 $0.093 fallen by 35.86%
$19 PainChek secures A$5.5m note to fund US expansion 22 May 2026 9:05AM $0.130 $0.093 fallen by 28.46%
$19 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 11:18AM $0.150 $0.093 fallen by 38%
$19 Notification of cessation of securities - PCK 14 Apr 2026 3:18PM $0.195 $0.093 fallen by 52.31%
$19 Landmark Sabra North America deployment targeting 20k beds 14 Apr 2026 9:19AM $0.150 $0.093 fallen by 38%
$19 Notification of cessation of securities - PCK 27 Mar 2026 2:34PM $0.195 $0.093 fallen by 52.31%
$19 PainChek reports material sales momentum in UK 26 Mar 2026 8:54AM $0.140 $0.093 fallen by 33.57%
$19 PainChek to present at NWR Virtual Healthcare Conference 24 Mar 2026 9:13AM $0.140 $0.093 fallen by 33.57%
$19 Notification of cessation of securities - PCK 4 Mar 2026 9:50AM $0.170 $0.093 fallen by 45.29%
$19 Half Yearly Report and Accounts 27 Feb 2026 2:19PM $0.170 $0.093 fallen by 45.29%
$19 Update - Notification regarding unquoted securities - PCK 12 Feb 2026 8:48AM $0.240 $0.093 fallen by 61.25%
$19 Notification regarding unquoted securities - PCK 11 Feb 2026 3:13PM $0.235 $0.093 fallen by 60.43%
$19 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 9:07AM $0.270 $0.093 fallen by 65.56%
$19 PainChek Business Update 30 Jan 2026 9:07AM $0.270 $0.093 fallen by 65.56%
$19 PainChek gains access to RTM reimbursement in USA 29 Jan 2026 8:51AM $0.265 $0.093 fallen by 64.91%
$19 Quarterly update & Appendix 4C webinar 28 Jan 2026 9:41AM $0.270 $0.093 fallen by 65.56%
$19 Change of Director's Interest Notice x 5 30 Dec 2025 1:27PM $0.300 $0.093 fallen by 69%
$19 Notification of cessation of securities - PCK 30 Dec 2025 1:23PM $0.300 $0.093 fallen by 69%
$19 Application for quotation of securities - PCK 24 Dec 2025 1:06PM $0.295 $0.093 fallen by 68.47%
$19 Notice under s708A(5)(e) of the Corporations Act 2001 (Cth) 23 Dec 2025 2:38PM $0.290 $0.093 fallen by 67.93%
$19 Change of Director's Interest Notice x2 23 Dec 2025 2:34PM $0.290 $0.093 fallen by 67.93%
$19 Application for quotation of securities - PCK 23 Dec 2025 2:18PM $0.290 $0.093 fallen by 67.93%
$19 Application for quotation of securities - PCK 12 Dec 2025 12:27PM $0.340 $0.093 fallen by 72.65%
$19 Results of Meeting 26 Nov 2025 5:47PM $0.039 $0.093 risen by 138.46%

26 - 50 of 481 results

Page 2 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.